Mirati Therapeutics has joined forces with MD Anderson Cancer Center to expand the study of its two KRAS inhibitors. The pact will enable Mirati to tap into MD Anderson’s clinical trial capabilities as it seeks to position adagrasib and MRTX1133 as treatments for multiple solid tumor types.

Last year, AbbVie decided to walk away from a pact with gene editing biotech Editas that was originally penned via its new buyout, Allergan.

Former Biogen Chief Executive Officer James C. Mullen has leapt from his leadership role at Patheon N.V., a pharmaceutical contract development and manufacturing organization, to take the helm at genome editing company Editas Medicine.

Team’s Research Addressed Changes in Seizures During Pregnancy

BOSTON — Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the appointments of Owen Wallace, Ph.D., as Chief Scientific Officer and Silvia Buonamici, Ph.D., as Senior Vice President, Drug Discovery Biology, as the company continues to expand its executive leadership team. Drs. Wallace and Buonamici will oversee the research and development of the company’s pipeline of molecular glue degrader programs.

Saskatoon, Saskatchewan –  MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company“, “MustGrow“) is pleased to announce further laboratory results of its mustard-derived natural biopesticide on the disease Fusarium wilt TR4 (“Fusarium wilt TR4“). Fusarium wilt TR4 (previously referred to as the Panama Disease) is a devastating pathogen ravaging the $25 billion global banana industry. Testing and reporting in this second Colombia study was completed by a different third party independent laboratory than was used in the first study to add further validation.

Immune-stimulating antibodies that target the receptor CD40 are emerging as promising therapies for pancreatic cancer, but they’ve only shrunk tumors in about half of patients who received them, along with chemotherapy, in clinical trials.

Over the course of 2020, Sanofi saw significant growth in its specialty care sales primarily driven by its blue-chip asset, Dupixent, as well as an increase in vaccine sales that were driven by demand for differentiated influenza vaccines, the company announced in its year-end financial report.

The FDA has cleared an artificial intelligence program designed to predict which patients in an intensive care unit will begin to deteriorate, giving clinicians up to eight hours of advanced warning and time to prepare.

GE Healthcare has offloaded its molecular breast cancer imaging assets for an undisclosed sum in a deal with newcomer SmartBreast.